688513 苑东生物
已收盘 03-30 15:00:00
资讯
新帖
简况
苑东生物涨7.05%，华源证券一周前给出“买入”评级
证券之星 · 03-27 16:13
苑东生物涨7.05%，华源证券一周前给出“买入”评级
3月10日苑东生物涨8.86%，博时主题LOF基金重仓该股
证券之星 · 03-10
3月10日苑东生物涨8.86%，博时主题LOF基金重仓该股
每周股票复盘：苑东生物（688513）2025年净利增18.89%
证券之星 · 03-01
每周股票复盘：苑东生物（688513）2025年净利增18.89%
苑东生物（688513）披露2025年度业绩快报公告，2月27日股价下跌0.66%
证券之星 · 02-27
苑东生物（688513）披露2025年度业绩快报公告，2月27日股价下跌0.66%
苑东生物最新公告：公司13个产品拟中选国家组织集采药品协议期满品种接续采购
证券之星 · 02-11
苑东生物最新公告：公司13个产品拟中选国家组织集采药品协议期满品种接续采购
苑东生物(688513.SH)：EP-0210单抗注射液I期临床试验完成首例受试者给药
智通财经 · 02-09
苑东生物(688513.SH)：EP-0210单抗注射液I期临床试验完成首例受试者给药
2月6日苑东生物跌5.01%，博时主题LOF基金重仓该股
证券之星 · 02-06
2月6日苑东生物跌5.01%，博时主题LOF基金重仓该股
每周股票复盘：苑东生物（688513）EP-0226片I期临床完成首例给药
证券之星 · 02-01
每周股票复盘：苑东生物（688513）EP-0226片I期临床完成首例给药
苑东生物（688513）披露EP-0226片I期临床试验完成首例受试者给药，1月29日股价上涨4.61%
证券之星 · 01-29
苑东生物（688513）披露EP-0226片I期临床试验完成首例受试者给药，1月29日股价上涨4.61%
每周股票复盘：苑东生物（688513）水合氯醛糖浆获批上市
证券之星 · 01-25
每周股票复盘：苑东生物（688513）水合氯醛糖浆获批上市
苑东生物最新公告：全资子公司水合氯醛糖浆获得药品注册证书
证券之星 · 01-22
苑东生物最新公告：全资子公司水合氯醛糖浆获得药品注册证书
1月8日苑东生物涨6.39%，博时研究优选LOF基金重仓该股
证券之星 · 01-08
1月8日苑东生物涨6.39%，博时研究优选LOF基金重仓该股
苑东生物涨6.39%，太平洋二个月前给出“买入”评级
证券之星 · 01-08
苑东生物涨6.39%，太平洋二个月前给出“买入”评级
每周股票复盘：苑东生物（688513）HP-001胶囊完成首例受试者给药
证券之星 · 01-02
每周股票复盘：苑东生物（688513）HP-001胶囊完成首例受试者给药
苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%
证券之星 · 2025-12-30
苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%
每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准
证券之星 · 2025-12-28
每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准
苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准
智通财经 · 2025-12-24
苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准
苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%
证券之星 · 2025-12-10
苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%
苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书
智通财经 · 2025-12-09
苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书
苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查
证券之星 · 2025-11-27
苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查
暂无数据
公司概况
公司名称：
成都苑东生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-09-02
主营业务：
成都苑东生物制药股份有限公司的主营业务是化学原料药、高端化学药品及生物药品研发、生产、销售。公司的主要产品是高端化学药品、创新药、原料药。
发行价格：
44.36
{"stockData":{"symbol":"688513","market":"SH","secType":"STK","nameCN":"苑东生物","latestPrice":66.35,"timestamp":1774854000000,"preClose":66.38,"halted":0,"volume":3682892,"delay":0,"changeRate":-0.0005,"floatShares":177000000,"shares":177000000,"eps":1.3674,"marketStatus":"已收盘","change":-0.03,"latestTime":"03-30 15:00:00","open":66,"high":69.49,"low":65,"amount":247000000,"amplitude":0.0676,"askPrice":66.35,"askSize":127,"bidPrice":66.19,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.3674,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774920600000},"marketStatusCode":5,"adr":0,"adjPreClose":66.38,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774834200000,1774841400000],[1774846800000,1774854000000]],"highLimit":73.02,"lowLimit":59.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":176532256,"isCdr":false,"pbRate":4.09,"roa":"--","peRate":48.522744,"roe":"7.93%","epsLYR":1.36,"committee":-0.71308,"marketValue":11713000000,"turnoverRate":0.0209,"status":1,"afterMarket":{"amount":0,"volume":0,"close":66.35,"buyVolume":0,"sellVolume":0,"time":1774856037558,"indexStatus":"已收盘 03-30 15:30:00","preClose":66.38},"floatMarketCap":11713000000},"requestUrl":"/m/hq/s/688513/tweets","defaultTab":"tweets","newsList":[{"id":"2622849392","title":"苑东生物涨7.05%，华源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849392?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:13","pubTimestamp":1774599218,"startTime":"0","endTime":"0","summary":"今日苑东生物涨7.05%，收盘报66.38元。2026年3月18日，华源证券研究员刘闯发布了对苑东生物的研报《主业稳健向上，分子胶平台稀缺性突出》，该研报对苑东生物给出“买入”评级。我们选取海思科，普洛药业，恩华药业，奥赛康作为可比公司，考虑到公司开展制剂及原料药国际化顺利且布局大量创新药管线，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为招商证券的梁广楷。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688513"],"gpt_icon":0},{"id":"2618980639","title":"3月10日苑东生物涨8.86%，博时主题LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980639?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:22","pubTimestamp":1773130953,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日苑东生物涨8.86%，收盘报62.28元，换手率1.88%，成交量3.32万手，成交额2.05亿元。重仓苑东生物的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家；过去90天内机构目标均价为87.6。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共34家，其中持有数量最多的公募基金为博时基金的博时主题LOF。博时主题LOF目前规模为52.28亿元，最新净值1.25，较上一交易日下跌0.79%，近一年上涨25.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160505","688513","BK0239"],"gpt_icon":0},{"id":"2616684540","title":"每周股票复盘：苑东生物（688513）2025年净利增18.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616684540","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616684540?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:04","pubTimestamp":1772305453,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，苑东生物报收于60.0元，较上周的64.39元下跌6.82%。本周，苑东生物2月24日盘中最高价报65.09元。本周关注点来自业绩披露要点：苑东生物2025年归属净利润同比增长18.89%来自公司公告汇总：受国家集采影响收入微降，利润因成本管控实现增长业绩披露要点苑东生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利2.832亿元，同比增长18.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2614850952","title":"苑东生物（688513）披露2025年度业绩快报公告，2月27日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614850952","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614850952?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:32","pubTimestamp":1772206335,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，苑东生物报收于60.0元，较前一交易日下跌0.66%，最新总市值为105.92亿元。该股当日开盘60.13元，最高61.09元，最低59.4元，成交额达7138.58万元，换手率为0.67%。近日，成都苑东生物制药股份有限公司发布2025年度业绩快报，营业总收入为133,139.76万元，同比下降1.36%；归属于母公司所有者的净利润为28,324.83万元，同比增长18.89%。总资产为379,885.73万元，较期初增长11.73%；归属于母公司的所有者权益为293,202.71万元，增长8.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2610807999","title":"苑东生物最新公告：公司13个产品拟中选国家组织集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610807999","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610807999?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:28","pubTimestamp":1770802137,"startTime":"0","endTime":"0","summary":"苑东生物公告称，公司参与了由江苏省、河南省和广东省牵头组织的原国家组织集采1-8批协议期满品种接续采购的申报工作，共有13个产品拟中选，包括富马酸比索洛尔片、依托考昔片等。采购周期为2026年2月10日起至2028年12月31日，对公司2025年度经营业绩不构成影响。尽管部分产品中选价格较原销售价格有所下降，但公司有13个产品拟中选，若后续签订并执行采购合同，仍可稳固现有市场份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2610362406","title":"苑东生物(688513.SH)：EP-0210单抗注射液I期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610362406","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610362406?lang=zh_cn&edition=full","pubTime":"2026-02-09 18:08","pubTimestamp":1770631680,"startTime":"0","endTime":"0","summary":"智通财经APP讯，苑东生物 发布公告，公司全资子公司成都优洛生物科技有限公司自主研发的1类生物药EP-0210单抗注射液正在开展用于治疗炎症性肠病的I期临床试验，于近日完成首例受试者给药。EP-0210单抗注射液是一款靶向人肿瘤坏死因子样配体1A的人源化IgG1单克隆抗体药物，拟定适应症为炎症性肠病，其作用机制是通过高效结合人TL1A，阻止TL1A介导的促炎症信号通路，从而发挥治疗炎症性肠病的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EP","688513","BK4213","BK0239"],"gpt_icon":0},{"id":"2609634145","title":"2月6日苑东生物跌5.01%，博时主题LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609634145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609634145?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:32","pubTimestamp":1770366774,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日苑东生物跌5.01%，收盘报66.21元，换手率1.91%，成交量3.37万手，成交额2.27亿元。重仓苑东生物的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家；过去90天内机构目标均价为87.6。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共34家，其中持有数量最多的公募基金为博时基金的博时主题LOF。博时主题LOF目前规模为52.28亿元，最新净值1.263，较上一交易日下跌1.33%，近一年上涨27.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","160505","BK0239"],"gpt_icon":0},{"id":"2608772860","title":"每周股票复盘：苑东生物（688513）EP-0226片I期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2608772860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608772860?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:15","pubTimestamp":1769886913,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，苑东生物报收于61.6元，较上周的58.58元上涨5.16%。本周，苑东生物1月30日盘中最高价报62.5元。本周关注点公司公告汇总：EP-0226片I期临床试验完成首例受试者给药。该I期临床试验为单中心、随机、双盲、安慰剂对照、剂量递增研究，旨在评估药物在健康受试者中的安全性、耐受性、药代动力学特征及对QTc间期的影响。截至公告日，单剂量给药阶段第1剂量组已完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2607035256","title":"苑东生物（688513）披露EP-0226片I期临床试验完成首例受试者给药，1月29日股价上涨4.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607035256","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607035256?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:30","pubTimestamp":1769697040,"startTime":"0","endTime":"0","summary":"近日，成都苑东生物制药股份有限公司与中国科学院上海药物研究所、中科中山药物创新研究院共同研发的1类化学创新药EP-0226片，完成用于治疗神经病理性疼痛的I期临床试验首例受试者给药。该I期临床试验为单中心、随机、双盲、安慰剂对照、剂量递增研究，旨在评估药物在健康受试者中的安全性、耐受性、药代动力学特征及对QTc间期的影响。截至公告日，单剂量给药阶段第1剂量组已完成首例受试者给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2606237302","title":"每周股票复盘：苑东生物（688513）水合氯醛糖浆获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606237302","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606237302?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:30","pubTimestamp":1769283032,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，苑东生物报收于58.58元，较上周的59.0元下跌0.71%。本周，苑东生物1月19日盘中最高价报59.47元。本周关注点公司公告汇总：苑东生物子公司水合氯醛糖浆获药品注册证书。公司公告汇总苑东生物：关于自愿披露2类改良型新药水合氯醛糖浆获得药品注册证书的公告成都苑东生物制药股份有限公司全资子公司成都硕德药业有限公司收到国家药监局核准签发的《药品注册证书》，其申报的2类改良型新药水合氯醛糖浆获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2605462999","title":"苑东生物最新公告：全资子公司水合氯醛糖浆获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462999","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462999?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:10","pubTimestamp":1769076629,"startTime":"0","endTime":"0","summary":"苑东生物(688513.SH)公告称，全资子公司硕德药业近日收到国家药监局核准签发的《药品注册证书》，药品名称为水合氯醛糖浆，适应症为儿童检查、操作前的镇静、催眠。该药品为公司首款获得批准的2类改良型新药，丰富了公司麻醉镇痛领域产品管线，目前尚未实现销售，不会对公司近期业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2601356339","title":"1月8日苑东生物涨6.39%，博时研究优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356339?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:36","pubTimestamp":1767857760,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日苑东生物涨6.39%创60日新高，收盘报63.62元，换手率2.62%，成交量4.62万手，成交额2.97亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为博时基金的博时研究优选LOF。博时研究优选LOF目前规模为9.08亿元，最新净值1.0243，较上一交易日上涨0.65%，近一年上涨46.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160916","BK0239","688513"],"gpt_icon":0},{"id":"2601395356","title":"苑东生物涨6.39%，太平洋二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601395356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601395356?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:35","pubTimestamp":1767857750,"startTime":"0","endTime":"0","summary":"今日苑东生物（688513）涨6.39%，收盘报63.62元。2025年10月31日，太平洋研究员谭紫媚,张懿发布了对苑东生物的研报《苑东生物：新产品贡献增量，加快全面创新转型》，该研报对苑东生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为83.87%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为招商证券的梁广楷。苑东生物（688513）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","601099"],"gpt_icon":0},{"id":"2600003655","title":"每周股票复盘：苑东生物（688513）HP-001胶囊完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2600003655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600003655?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:46","pubTimestamp":1767293170,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，苑东生物报收于59.95元，较上周的57.28元上涨4.66%。本周关注点公司公告汇总：HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药公司公告汇总苑东生物：关于自愿披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药的公告成都苑东生物制药股份有限公司控股子公司上海超阳药业自主研发的1类创新药HP-001胶囊联合地塞米松治疗复发难治多发性骨髓瘤的I/II期临床试验已完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2595881795","title":"苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595881795","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595881795?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:44","pubTimestamp":1767087896,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，苑东生物报收于60.51元，较前一交易日上涨1.7%，最新总市值为106.82亿元。该股当日开盘58.3元，最高61.16元，最低58.3元，成交额达8723.49万元，换手率为0.82%。公司近日发布公告称，控股子公司上海超阳药业自主研发的1类创新药HP-001胶囊联合地塞米松治疗复发难治多发性骨髓瘤的I/II期临床试验已完成首例受试者给药。本次联合用药临床试验旨在评估其在复发难治多发性骨髓瘤患者中的安全性、耐受性、药代动力学及疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2594826247","title":"每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2594826247","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594826247?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:47","pubTimestamp":1766868426,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，苑东生物报收于59.95元，较上周的57.28元上涨4.66%。本周，苑东生物12月26日盘中最高价报60.39元。本周关注点公司公告汇总：亚甲蓝注射液获得美国FDA药品注册批准，ANDA号219550。公司公告汇总苑东生物：关于自愿披露亚甲蓝注射液获得美国FDA药品注册批准的公告成都苑东生物制药股份有限公司全资子公司成都硕德药业有限公司收到美国FDA通知，其申报的亚甲蓝注射液简化新药申请获得批准，ANDA号219550，规格50mg/10mL。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2593784084","title":"苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593784084","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593784084?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:00","pubTimestamp":1766566836,"startTime":"0","endTime":"0","summary":"智通财经APP讯，苑东生物(688513.SH)发布公告，公司全资子公司成都硕德药业有限公司(简称“硕德药业”)于近日收到美国食品药品监督管理局(简称“美国FDA”)的通知，硕德药业向美国FDA申报的亚甲蓝注射液的简化新药申请(ANDA，即美国仿制药申请)获得正式批准。亚甲蓝注射液的活性成分为亚甲蓝，适应症为用于治疗儿童和成人获得性高铁血红蛋白血症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2590913583","title":"苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590913583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590913583?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:51","pubTimestamp":1765360285,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，苑东生物报收于56.35元，较前一交易日上涨1.75%，最新总市值为99.48亿元。该股当日开盘55.38元，最高56.58元，最低54.75元，成交额达4341.98万元，换手率为0.44%。公司近日发布公告称，成都苑东生物制药股份有限公司收到国家药品监督管理局核准签发的布瑞哌唑片药品注册证书，批准其生产1mg、2mg、4mg规格的布瑞哌唑片，注册分类为化学药品4类，视同通过一致性评价。公告显示，该产品2025年上半年销售额较低，对公司近期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000028968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2590831173","title":"苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590831173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590831173?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:32","pubTimestamp":1765272750,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 苑东生物(688513.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的《药品注册证书》。布瑞哌唑片活性成分为布瑞哌唑，适应症为用于治疗成人精神分裂症。布瑞哌唑片最早由日本大冢制药(Otsuka Pharmaceutical Co.，Ltd.)开发，于2015年7月在美国获批上市，商品名为Rexulti®，于2024年6月进口中国。国家药监局官网显示，该产品国内目前仅有进口原研药上市，公司该药品是国内首家按新注册分类获批的仿制药，视同通过一致性评价","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2586246064","title":"苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2586246064","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586246064?lang=zh_cn&edition=full","pubTime":"2025-11-27 17:50","pubTimestamp":1764237029,"startTime":"0","endTime":"0","summary":"苑东生物(688513.SH)公告称，公司全资子公司硕德药业于2025年5月接受了美国FDA的现行药品生产质量管理规范（cGMP）和生物研究监测（BIMO）现场检查，涉及产品为盐酸纳洛酮鼻喷剂。近日，硕德药业收到FDA出具的两份现场检查报告，以零缺陷通过上述现场检查。此次检查通过有利于加快公司已申报美国ANDA产品的获批进度，但短期内对公司经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700026552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774858280649,"stockEarnings":[{"period":"1week","weight":0.138},{"period":"1month","weight":0.0875},{"period":"3month","weight":0.1073},{"period":"6month","weight":0.2102},{"period":"1year","weight":1.0772},{"period":"ytd","weight":0.0785}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都苑东生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6482人(较上一季度增加18.67%)","perCapita":"27234股","listingDate":"2020-09-02","address":"四川省成都市郫都区高新区西源大道8号","registeredCapital":"17653万元","survey":" 成都苑东生物制药股份有限公司的主营业务是化学原料药、高端化学药品及生物药品研发、生产、销售。公司的主要产品是高端化学药品、创新药、原料药。","listedPrice":44.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"苑东生物,688513,苑东生物股票,苑东生物股票老虎,苑东生物股票老虎国际,苑东生物行情,苑东生物股票行情,苑东生物股价,苑东生物股市,苑东生物股票价格,苑东生物股票交易,苑东生物股票购买,苑东生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}